The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia.
 
Claudia A.M. Fulgenzi
No Relationships to Disclose
 
Talal El Zarif
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Elio Adib
Employment - Amgen (I)
 
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate Bladder Cancer
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer
 
Thomas Urban Marron
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Boehringer Ingelheim; Celldex; DBV Technologies; Glenmark; NGM Biopharmaceuticals; Regeneron; Surface Oncology
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
Travel, Accommodations, Expenses - Abbvie; Genentech
 
Michael Lorentsen
No Relationships to Disclose
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Javier Baena
Honoraria - AstraZeneca Spain; AstraZeneca Spain; Bristol-Myers Squibb/Pfizer
Consulting or Advisory Role - Access Oncology; AstraZeneca Spain; Roche; Roche
Expert Testimony - Roche
Travel, Accommodations, Expenses - Janssen Oncology; MSD; MSD; Roche; Roche
 
Celina Ang
No Relationships to Disclose
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb Italy; Eisai; Gilead Sciences; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Elevar Therapeutics; Exelixis; Genenta Science; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks
Research Funding - Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Alessandro Parisi
No Relationships to Disclose
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Pei-Chang Lee
No Relationships to Disclose
 
Neehar Parikh
Consulting or Advisory Role - Eisai; Eisai; Exelixis; Gilead Sciences; Lilly
Research Funding - Exact Sciences (Inst); Exelixis (Inst); Genentech (Inst)
 
Matthias Pinter
No Relationships to Disclose
 
Alessio Cortellini
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IQvia; MSD Oncology; OncoC4
Speakers' Bureau - AstraZeneca; Eisai
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
David James Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Lift Biosciences; Mursla Bio; Roche/Genentech; Starpharma
Consulting or Advisory Role - AstraZeneca; Da Volterra; EISAI; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley